JMP Securities Reiterates “Market Outperform” Rating for DBV Technologies (NASDAQ:DBVT)

DBV Technologies (NASDAQ:DBVT)‘s stock had its “market outperform” rating restated by equities researchers at JMP Securities in a research report issued to clients and investors on Tuesday,Benzinga reports. They currently have a $10.00 target price on the stock. JMP Securities’ price target would indicate a potential upside of 203.95% from the company’s previous close.

DBVT has been the topic of several other research reports. HC Wainwright upped their price objective on DBV Technologies from $25.00 to $35.00 and gave the company a “buy” rating in a research note on Thursday, October 24th. StockNews.com initiated coverage on DBV Technologies in a research report on Sunday. They set a “hold” rating on the stock.

DBV Technologies Stock Performance

DBVT opened at $3.29 on Tuesday. The company has a market capitalization of $67.68 million, a P/E ratio of -0.73 and a beta of 0.64. The company has a 50-day moving average of $3.45 and a 200-day moving average of $4.04. DBV Technologies has a 1-year low of $2.20 and a 1-year high of $10.70.

About DBV Technologies

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow’s milk protein allergy and eosinophilic esophagitis.